「trial」の検索結果

Think and work like an expert Critical Care Researcher. Use when a task calls for Critical Care Researcher judgment. Reasons from acute physiology trajectories, modular organ dysfunction, and cluster-aware trial design through APACHE/SAPS/SOFA scoring, Berlin/Sepsis-3/KDIGO definitions, MIMIC-IV phenotyping, and target-trial emulation with clone-censor-weighting while treating immortal-time bias, cluster contamination, competing risks from early death, and sepsis-phenotype cohort inflation as first-class failure modes.

日本語の概要は準備中です。原文の説明を表示しています。

Reads, validates, and prepares CDISC SDTM and ADaM clinical trial data for analysis. Covers SDTM domain joins (DM, AE, EX, VS, LB, DS), ADaM architecture (ADSL, BDS, OCCDS, ADTTE) with traceability, treatment-emergent AE conventions, baseline derivation, SUPPQUAL/NSV handling, Define-XML 2.1, and Pinnacle 21 / CORE validation. Use when working with clinical trial datasets in CDISC SDTM/ADaM format, preparing analysis-ready data, or validating for regulatory submission.

日本語の概要は準備中です。原文の説明を表示しています。

Performs time-to-event analysis for clinical trials including Cox proportional hazards regression with PH diagnostics, restricted mean survival time (RMST) under non-PH, competing risks via Fine-Gray vs cause-specific Cox, weighted log-rank and MaxCombo for non-proportional hazards, recurrent events (Andersen-Gill, PWP, WLW), and interval-censored data. Use when analyzing time-to-event endpoints (OS, PFS, DOR, TTR, TTNT) in oncology or other clinical trials.

日本語の概要は準備中です。原文の説明を表示しています。

Designs adaptive clinical trials including group-sequential (O'Brien-Fleming, Pocock, Lan-DeMets spending), sample-size re-estimation (blinded Friede-Kieser, unblinded Cui-Hung-Wang, Mehta-Pocock promising zone), seamless Phase 2/3 with treatment-arm selection, population enrichment, and response-adaptive randomisation. Covers FDA 2019 Final Adaptive Designs Guidance, FDA 2022 Master Protocols, and ICH E20 Step 2b/3 draft (June 2025, NOT final). Use when planning interim analyses, sample-size re-estimation, or master/platform-trial designs.

日本語の概要は準備中です。原文の説明を表示しています。

Patterns for designing and analyzing clinical trials, including survival analysis, endpoint selection, sample size calculation, interim analyses, and regulatory considerations. Covers FDA/EMA guidelines and modern adaptive designs. Use when ", " mentioned.

日本語の概要は準備中です。原文の説明を表示しています。

调香师与香水 (调香师 / 香水 (Perfumery & Fragrance) — 香水创作与香气调配的职业认知操作系统，从业者/调香师/评香师/学习者视角。覆盖: (a) 第一性张力 — codifiable 理论层 (原料知识/香料化学/嗅觉家族分类/accord 和弦/配方结构 %/挥发度金字塔/IFRA 法规) ⇄ tacit 校准层 (嗅觉记忆/闻香训练/「the nose」/创作直觉/盲嗅识别)，这行的核心矛盾是「可背诵的原料与公式」与「不可言传的嗅觉记忆与品味」之间，嗅觉记忆是极致 tacit 技能; (b) 法系传统 vs 分子/合成派 — 法国 Grasse 天然香料 + haute parfumerie 艺术传统 (天然精油/原精/学徒制) vs 现代分子派 (aroma chemicals 香基/captives 专利分子/headspace 顶空捕香/功能香精)，两套对「香水是什么」的世界观; (c) 培养/传承 — ISIPCA (凡尔赛香水学校) + 四大香精公司内部调香学校 (Givaudan/Firmenich(DSM-Firmenich)/IFF/Symrise) + 学徒制 + 「鼻子」tacit 校准; 角色分工: perfumer(parfumeur 调香师) vs evaluator(评香师) vs flavorist(食用香精师); (d) 行业结构 — 四大香精公司寡头 (Givaudan/DSM-Firmenich/IFF/Symrise) + Mane/Robertet/Takasago，为品牌做 B2B 命题创作 (the brief → creation → mods 模型); vs niche/indie 小众独立香水 (artisanal/直营); 天然 (Grasse/精油) vs 合成 (香基/captives) 的成本与可持续之争; (e) 创作层 — 香调金字塔 (top/heart/base notes 前中后调)、accord 和弦、配方 (酒精中 % 浓度)、浓度分级 (parfum/EDP/EDT/EDC)、调香师的「香风琴」orgue、trials/mods 试样迭代、weighing 称量精度; (f) 法规与安全 — IFRA standards (原料限用)、EU 致敏原标签 (26→80+ allergens)、REACH、橡苔/atranol 限用、经典香水 (Mitsouko/Chanel No.5) 因法规被迫重配 (reformulation) 与创作自由之张力; (g) 评价/批评 — Luca Turin & Tania Sanchez (《Perfumes: The Guide》《The Secret of Scent》气味的科学)、香评人、Fragrantica/Basenotes 社区、vintage vs reformulation 之争、niche vs designer 之争。学派分歧: 法系天然传统派 vs 分子合成派、天然纯粹派 vs 合成实用派、haute parfumerie/niche 艺术派 vs mass designer 商业派、「鼻子=艺术家」vs「调香师=香气工程师/技师」、嗅觉科学之争 (Luca Turin 振动理论 vs 主流形状/受体理论)。不含: 香薰蜡烛/家居香氛纯生产营销、芳香疗法健康宣称 (aromatherapy)、纯化妆品配方学 (超出香精范畴)、DIY 家用香氛套件、精油传销/MLM。) Master OS — automated mastery of 调香师 / 香水 (Perfumery & Fragrance) — 香水创作与香气调配的职业认知操作系统，从业者/调香师/评香师/学习者视角。覆盖: (a) 第一性张力 — codifiable 理论层 (原料知识/香料化学/嗅觉家族分类/accord 和弦/配方结构 %/挥发度金字塔/IFRA 法规) ⇄ tacit 校准层 (嗅觉记忆/闻香训练/「the nose」/创作直觉/盲嗅识别)，这行的核心矛盾是「可背诵的原料与公式」与「不可言传的嗅觉记忆与品味」之间，嗅觉记忆是极致 tacit 技能; (b) 法系传统 vs 分子/合成派 — 法国 Grasse 天然香料 + haute parfumerie 艺术传统 (天然精油/原精/学徒制) vs 现代分子派 (aroma chemicals 香基/captives 专利分子/headspace 顶空捕香/功能香精)，两套对「香水是什么」的世界观; (c) 培养/传承 — ISIPCA (凡尔赛香水学校) + 四大香精公司内部调香学校 (Givaudan/Firmenich(DSM-Firmenich)/IFF/Symrise) + 学徒制 + 「鼻子」tacit 校准; 角色分工: perfumer(parfumeur 调香师) vs evaluator(评香师) vs flavorist(食用香精师); (d) 行业结构 — 四大香精公司寡头 (Givaudan/DSM-Firmenich/IFF/Symrise) + Mane/Robertet/Takasago，为品牌做 B2B 命题创作 (the brief → creation → mods 模型); vs niche/indie 小众独立香水 (artisanal/直营); 天然 (Grasse/精油) vs 合成 (香基/captives) 的成本与可持续之争; (e) 创作层 — 香调金字塔 (top/heart/base notes 前中后调)、accord 和弦、配方 (酒精中 % 浓度)、浓度分级 (parfum/EDP/EDT/EDC)、调香师的「香风琴」orgue、trials/mods 试样迭代、weighing 称量精度; (f) 法规与安全 — IFRA standards (原料限用)、EU 致敏原标签 (26→80+ allergens)、REACH、橡苔/atranol 限用、经典香水 (Mitsouko/Chanel No.5) 因法规被迫重配 (reformulation) 与创作自由之张力; (g) 评价/批评 — Luca Turin & Tania Sanchez (《Perfumes: The Guide》《The Secret of Scent》气味的科学)、香评人、Fragrantica/Basenotes 社区、vintage vs reformulation 之争、niche vs designer 之争。学派分歧: 法系天然传统派 vs 分子合成派、天然纯粹派 vs 合成实用派、haute parfumerie/niche 艺术派 vs mass designer 商业派、「鼻子=艺术家」vs「调香师=香气工程师/技师」、嗅觉科学之争 (Luca Turin 振动理论 vs 主流形状/受体理论)。不含: 香薰蜡烛/家居香氛纯生产营销、芳香疗法健康宣称 (aromatherapy)、纯化妆品配方学 (超出香精范畴)、DIY 家用香氛套件、精油传销/MLM。: top builders' mental models, tool stack, current workflows, jargon, and where to keep up. Trigger this skill when the user works on 调香师 / 香水 (Perfumery & Fragrance) — 香水创作与香气调配的职业认知操作系统，从业者/调香师/评香师/学习者视角。覆盖: (a) 第一性张力 — codifiable 理论层 (原料知识/香料化学/嗅觉家族分类/accord 和弦/配方结构 %/挥发度金字塔/IFRA 法规) ⇄ tacit 校准层 (嗅觉记忆/闻香训练/「the nose」/创作直觉/盲嗅识别)，这行的核心矛盾是「可背诵的原料与公式」与「不可言传的嗅觉记忆与品味」之间，嗅觉记忆是极致 tacit 技能; (b) 法系传统 vs 分子/合成派 — 法国 Grasse 天然香料 + haute parfumerie 艺术传统 (天然精油/原精/学徒制) vs 现代分子派 (aroma chemicals 香基/captives 专利分子/headspace 顶空捕香/功能香精)，两套对「香水是什么」的世界观; (c) 培养/传承 — ISIPCA (凡尔赛香水学校) + 四大香精公司内部调香学校 (Givaudan/Firmenich(DSM-Firmenich)/IFF/Symrise) + 学徒制 + 「鼻子」tacit 校准; 角色分工: perfumer(parfumeur 调香师) vs evaluator(评香师) vs flavorist(食用香精师); (d) 行业结构 — 四大香精公司寡头 (Givaudan/DSM-Firmenich/IFF/Symrise) + Mane/Robertet/Takasago，为品牌做 B2B 命题创作 (the brief → creation → mods 模型); vs niche/indie 小众独立香水 (artisanal/直营); 天然 (Grasse/精油) vs 合成 (香基/captives) 的成本与可持续之争; (e) 创作层 — 香调金字塔 (top/heart/base notes 前中后调)、ac

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill to reason like JoAnn E. Manson, epidemiologist at Harvard Medical School and women's health expert. Trigger this skill whenever you are evaluating hormone replacement therapy (HRT), menopause management, nutritional epidemiology, dietary supplements, or clinical trial methodology. Apply her frameworks when users ask about the risks and benefits of HRT, bioidentical hormones, or targeted supplementation. Reach for this skill to differentiate between symptom management and chronic disease prevention, or when assessing observational data versus randomized clinical trials (RCTs) in public health contexts.

日本語の概要は準備中です。原文の説明を表示しています。

Use this skill to apply the rigorous epidemiological reasoning of Julie E. Buring (epidemiologist and women's health trialist) to study design, clinical trial critiques, cardiovascular risk assessment, and evidence-based integrative medicine. Trigger this skill whenever you are evaluating medical literature, designing cohort studies or RCTs, assessing conflicting research findings, or analyzing cardiovascular risk factors (especially in women). Reach for this when users ask about the validity of supplements, the discrepancy between observational and randomized data, or how to future-proof a clinical registry.

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants to create or optimize in-app paywalls, upgrade screens, upsell modals, or feature gates. Also use when the user mentions "paywall," "upgrade screen," "upgrade modal," "upsell," "feature gate," "convert free to paid," "freemium conversion," "trial expiration screen," "limit reached screen," "plan upgrade prompt," "in-app pricing," "free users won't upgrade," "trial to paid conversion," or "how do I get users to pay." Use this for any in-product moment where you're asking users to upgrade. Distinct from public pricing pages (see cro) — this focuses on in-product upgrade moments where the user has already experienced value. For pricing decisions, see pricing.

日本語の概要は準備中です。原文の説明を表示しています。

Industrial production of iron and steel from ore to finished product — blast furnace, Bessemer converter, open-hearth, basic oxygen, electric arc, continuous casting, rolling, and secondary metallurgy. Covers the chemistry of decarburization, dephosphorization, and desulfurization, the metallurgy of plain carbon steels, the evolution from puddling and rolling to BOF and EAF, and the process-structure-property chain that makes mild steel the default structural material of the industrial era.

日本語の概要は準備中です。原文の説明を表示しています。

When the user wants to optimize signup, registration, account creation, or trial activation flows. Also use when the user mentions "signup conversions," "registration friction," "signup form optimization," "free trial signup," "reduce signup dropoff," or "account creation flow." For post-signup onboarding, see onboarding-cro. For lead capture forms (not account creation), see form-cro.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a SaaS founder is deciding on or building a product-led growth motion — assessing PLG readiness, choosing freemium vs free trial vs reverse trial, defining activation and PQLs, designing self-serve onboarding and conversion triggers, building viral loops, or setting up PLG metrics (NRG, activation rate, TTV, NDR, CAC payback) and cohort analysis. Also for hybrid product-led-sales design and PLG-vs-sales-led GTM decisions. Not for paid acquisition channel mix (use channel-expert) or the mechanics of price points and tiers (use pricing).

日本語の概要は準備中です。原文の説明を表示しています。

Product-led growth and customer-base growth for B2B SaaS. Use this skill for self-serve funnel work (activation, time-to-value, free trial vs freemium, PQL definition, in-product upgrade moments, sales-assist triggers), for the self-guided interactive product demo that runs in front of the login wall (demo portfolio and flow design, gated vs ungated policy, demo seed data and privacy, keeping a published demo in sync with the shipping product, step-level demo analytics), and for growing revenue from existing customers (adoption, expansion, churn-save, the self-serve cancel flow and failed-payment recovery, renewal marketing, net revenue retention, and champion tracking: watching the people who bought and used you at each customer, confirming a job change from evidence, and running both plays a move fires, the seat they left and the account they joined). Also triggers on: PLG, product-led growth, activation, aha moment, time to value, free trial, freemium, PQL, product qualified lead, onboarding, self-serve, customer marketing, expansion revenue, upsell, cross-sell, churn, retention, NRR, renewal, cancel flow, cancellation flow, save offer, exit survey, pause subscription, dunning, failed payment recovery, involuntary churn, people keep canceling, champion tracking, job change signals, job change alerts, our champion left, our champion changed jobs, customer alumni, former customers who moved to a new company, interactive demo, self-guided demo, product tour, click-through demo, demo automation, demo library, should our demo be gated, ungated demo, demo without a sales call, our demo is out of date, demo shows the old UI, put a demo on our homepage, demo completion rate, demo drop-off, try before you talk to sales.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a task needs the judgment of a Commercial and Industrial Electronics Repairer — diagnosing a VFD fault trip on a production line, tracing a PLC I/O fault back to the sensor, the wiring, or the ladder logic, selecting arc-flash PPE for live-panel diagnostic work, triaging multiple simultaneous down-lines by downtime-cost-per-hour, or deciding drive/board swap versus component-level repair.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a task needs the judgment of a Commercial/Industrial Designer — designing the form, ergonomics, and manufacturability of a physical product, choosing between manufacturing processes at a given volume, selecting materials/finishes under a cost or durability constraint, or planning a prototyping sequence before tooling commitment.

日本語の概要は準備中です。原文の説明を表示しています。

Use when a task needs the judgment of a Biostatistician — designing a clinical trial's sample size and analysis plan, choosing a survival-analysis or censoring-aware method, preparing a DSMB safety readout, or judging whether a trial's efficacy claim survives ITT vs. per-protocol scrutiny.

日本語の概要は準備中です。原文の説明を表示しています。

Cross-reference ENCODE data with PubMed, bioRxiv, ClinicalTrials.gov, Open Targets, GTEx, ClinVar, GWAS Catalog, gnomAD, Ensembl, and other scientific databases. Use when the user wants to find publications, preprints, or clinical trials related to ENCODE experiments, chain ENCODE data with other scientific MCP servers, or build translational pipelines from genomic data to clinical application.

日本語の概要は準備中です。原文の説明を表示しています。

Designing clinical trials — phases, randomization, endpoints, sample size, and CONSORT-compliant reporting.

日本語の概要は準備中です。原文の説明を表示しています。

Use when an ISV or consulting partner is creating, pricing, publishing, or maintaining an AgentExchange listing through the Partner Console — covers the listing plan, the 5-step Listing Builder workflow (Fill in the Basics, Set Pricing, Add Details, Link Your Solution, Grow Your Business), commercialization models (revenue share vs. annual fee vs. freemium), AgentExchange Checkout setup (Stripe connection, pricing plans, fees, geographic eligibility), Private Offers, Security Review gating, and post-publish listing updates. NOT for building the agent or managed package itself (use agentforce/agentforce-agent-creation and devops/second-generation-managed-packages), NOT for LMA/Trialforce licensing internals (use devops/isv-license-management-and-trialforce), and NOT for the customer-side install experience.

日本語の概要は準備中です。原文の説明を表示しています。

Drafts a Motion for Bail Reduction for criminal defense pretrial proceedings. Argues current bail is excessive under the Eighth Amendment using defendant financial circumstances, community ties, and flight-risk factors adapted to jurisdictional bail standards. Use when seeking bail modification, bail reduction, pretrial release, or excessive bail challenges.

日本語の概要は準備中です。原文の説明を表示しています。

Transforms police body camera transcripts into structured 10-section legal summaries with timestamp-cited verbatim statements, constitutional issue spotting, evidence inventory, and probable cause articulation. Maintains strict neutrality for all parties. Use when analyzing BWC footage for discovery, pre-trial prep, or trial. Trigger: body camera, BWC, body worn camera, officer footage, use of force review, incident summary.

日本語の概要は準備中です。原文の説明を表示しています。

Drafts an Appellee's Response Brief defending the trial court's judgment and arguing for affirmance. Covers standard of review analysis, record-based rebuttal, authority distinction, and procedural compliance. Trigger when drafting appellee briefs, response briefs, answering briefs, or defending trial court judgments on appeal.

日本語の概要は準備中です。原文の説明を表示しています。

Handle ethical requirements, IRB approval, trial registration, and pre-analysis plans for RCTs. Use when user mentions: research ethics, IRB, informed consent, trial registration, pre-analysis plan, PAP, data security, vulnerable populations, research transparency.

日本語の概要は準備中です。原文の説明を表示しています。

Implements multiplicity control for confirmatory clinical trials using graphical procedures (Bretz-Maurer-Hommel), gatekeeping (parallel, serial, mixed), Hochberg/Hommel/Holm with PRDS, and the closed-testing principle (Marcus-Peritz-Gabriel; Goeman 2021 admissibility). Covers FDA Multiple Endpoints Final Guidance (October 2022), graphical procedures via R gMCP, primary + key-secondary + subgroup hierarchies, and FWER vs FDR distinction. Use when designing the multiplicity strategy for confirmatory trials with multiple primary or key secondary endpoints.

日本語の概要は準備中です。原文の説明を表示しています。